The world is Aphria's oyster...investors see the potential..Germany is a lucrative cannabis market. The country has fully legalized cannabis for medical purposes and is ranked 13th in the world for per-capita cannabis use. Not only will the CC Pharma acquisition give Aphria more access to this market, but it could also help the company break into "broader pharmaceuticals"...... But will the deal send Aphrias stock higher?.... First, we need to look at how it will impact Aphrias ability to penetrate the German market: Distribution effects..... CC Pharma is a pharmaceutical distributor, meaning it delivers drugs to pharmacies (but does not manufacture them). The company is involved in importing and exporting drugs to and from Germany. Its supply chain reaches 13,000 German pharmacies in a country that has about 20,000 pharmacies in total. THIS IS A SIGNIFICANT REACH. By supplying cannabis to its new subsidiary, Aphria could potentially reach just shy of 75% of all German pharmacies. This would make Aphria a dominant player in the German medical cannabis market one of the most important in the world. GLTA